Cargando…
A cross‐sectional study of patients referred for HNF1B‐MODY genetic testing due to cystic kidneys and diabetes
BACKGROUND/OBJECTIVES: Patients referred for HNF1B testing present very heterogeneous phenotypes. Despite suggestive characteristics, many do not harbor mutations in HNF1B. Our objective was to evaluate the clinical characteristics of probands referred for HNF1B genetic testing through a nationwide...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons A/S
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217165/ https://www.ncbi.nlm.nih.gov/pubmed/31825128 http://dx.doi.org/10.1111/pedi.12959 |
_version_ | 1783532559784738816 |
---|---|
author | Sztromwasser, Paweł Michalak, Arkadiusz Małachowska, Beata Młudzik, Paulina Antosik, Karolina Hogendorf, Anna Zmysłowska, Agnieszka Borowiec, Maciej Młynarski, Wojciech Fendler, Wojciech |
author_facet | Sztromwasser, Paweł Michalak, Arkadiusz Małachowska, Beata Młudzik, Paulina Antosik, Karolina Hogendorf, Anna Zmysłowska, Agnieszka Borowiec, Maciej Młynarski, Wojciech Fendler, Wojciech |
author_sort | Sztromwasser, Paweł |
collection | PubMed |
description | BACKGROUND/OBJECTIVES: Patients referred for HNF1B testing present very heterogeneous phenotypes. Despite suggestive characteristics, many do not harbor mutations in HNF1B. Our objective was to evaluate the clinical characteristics of probands referred for HNF1B genetic testing through a nationwide monogenic diabetes screening program. METHODS: Probands tested for HNF1B mutations in the 2005‐2018 period (N = 50) were identified in the Polish Monogenic Diabetes Registry, which prospectively recruits primarily pediatric patients and their families on a nationwide scale. Variants that had been reported pathogenic were reassessed using criteria of the American College of Medical Genetics and Genomics (ACMG). A structured medical interview was performed with all available individuals, their parents, and/or their physicians. For each patient, HNF1B score was calculated based on available clinical information. RESULTS: The study group numbered 36 unrelated probands (28% lost to follow‐up): 14 with pathogenic or likely‐pathogenic variants in HNF1B, one with a variant of uncertain significance, and 21 negative for HNF1B mutations. Presence of cystic kidneys (OR = 9.17, 95% CI:1.87‐44.92), pancreatic abnormalities (OR = 15, 95% CI:1.55‐145.23), elevated liver enzymes (OR = 15, 95% CI:1.55‐145.23) best discriminated HNF1B‐positive cases from the negative ones. Presence of impaired glucose tolerance coupled with kidney disease in the proband and one parent was also highly predictive for HNF1B mutations (OR = 11.11, 95% CI:1.13‐109.36). HNF1B‐score with recommended cutoff distinguished patients with and without HNF1B findings with 100% sensitivity and 47.6% specificity. Addition of four clinical variables to select patients based on HNF1B score improved specificity to 71.4% (95% CI:47.8%‐88.7%) while retaining 100% sensitivity. CONCLUSIONS: Detailed medical interview may enable more accurate patient selection for targeted genetic testing. |
format | Online Article Text |
id | pubmed-7217165 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley & Sons A/S |
record_format | MEDLINE/PubMed |
spelling | pubmed-72171652020-05-13 A cross‐sectional study of patients referred for HNF1B‐MODY genetic testing due to cystic kidneys and diabetes Sztromwasser, Paweł Michalak, Arkadiusz Małachowska, Beata Młudzik, Paulina Antosik, Karolina Hogendorf, Anna Zmysłowska, Agnieszka Borowiec, Maciej Młynarski, Wojciech Fendler, Wojciech Pediatr Diabetes Monogenic Diabetes and Other Genetic Disorders of Glucose Metabolism BACKGROUND/OBJECTIVES: Patients referred for HNF1B testing present very heterogeneous phenotypes. Despite suggestive characteristics, many do not harbor mutations in HNF1B. Our objective was to evaluate the clinical characteristics of probands referred for HNF1B genetic testing through a nationwide monogenic diabetes screening program. METHODS: Probands tested for HNF1B mutations in the 2005‐2018 period (N = 50) were identified in the Polish Monogenic Diabetes Registry, which prospectively recruits primarily pediatric patients and their families on a nationwide scale. Variants that had been reported pathogenic were reassessed using criteria of the American College of Medical Genetics and Genomics (ACMG). A structured medical interview was performed with all available individuals, their parents, and/or their physicians. For each patient, HNF1B score was calculated based on available clinical information. RESULTS: The study group numbered 36 unrelated probands (28% lost to follow‐up): 14 with pathogenic or likely‐pathogenic variants in HNF1B, one with a variant of uncertain significance, and 21 negative for HNF1B mutations. Presence of cystic kidneys (OR = 9.17, 95% CI:1.87‐44.92), pancreatic abnormalities (OR = 15, 95% CI:1.55‐145.23), elevated liver enzymes (OR = 15, 95% CI:1.55‐145.23) best discriminated HNF1B‐positive cases from the negative ones. Presence of impaired glucose tolerance coupled with kidney disease in the proband and one parent was also highly predictive for HNF1B mutations (OR = 11.11, 95% CI:1.13‐109.36). HNF1B‐score with recommended cutoff distinguished patients with and without HNF1B findings with 100% sensitivity and 47.6% specificity. Addition of four clinical variables to select patients based on HNF1B score improved specificity to 71.4% (95% CI:47.8%‐88.7%) while retaining 100% sensitivity. CONCLUSIONS: Detailed medical interview may enable more accurate patient selection for targeted genetic testing. John Wiley & Sons A/S 2020-01-29 2020-05 /pmc/articles/PMC7217165/ /pubmed/31825128 http://dx.doi.org/10.1111/pedi.12959 Text en © 2019 The Authors. Pediatric Diabetes published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Monogenic Diabetes and Other Genetic Disorders of Glucose Metabolism Sztromwasser, Paweł Michalak, Arkadiusz Małachowska, Beata Młudzik, Paulina Antosik, Karolina Hogendorf, Anna Zmysłowska, Agnieszka Borowiec, Maciej Młynarski, Wojciech Fendler, Wojciech A cross‐sectional study of patients referred for HNF1B‐MODY genetic testing due to cystic kidneys and diabetes |
title | A cross‐sectional study of patients referred for HNF1B‐MODY genetic testing due to cystic kidneys and diabetes |
title_full | A cross‐sectional study of patients referred for HNF1B‐MODY genetic testing due to cystic kidneys and diabetes |
title_fullStr | A cross‐sectional study of patients referred for HNF1B‐MODY genetic testing due to cystic kidneys and diabetes |
title_full_unstemmed | A cross‐sectional study of patients referred for HNF1B‐MODY genetic testing due to cystic kidneys and diabetes |
title_short | A cross‐sectional study of patients referred for HNF1B‐MODY genetic testing due to cystic kidneys and diabetes |
title_sort | cross‐sectional study of patients referred for hnf1b‐mody genetic testing due to cystic kidneys and diabetes |
topic | Monogenic Diabetes and Other Genetic Disorders of Glucose Metabolism |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217165/ https://www.ncbi.nlm.nih.gov/pubmed/31825128 http://dx.doi.org/10.1111/pedi.12959 |
work_keys_str_mv | AT sztromwasserpaweł acrosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes AT michalakarkadiusz acrosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes AT małachowskabeata acrosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes AT młudzikpaulina acrosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes AT antosikkarolina acrosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes AT hogendorfanna acrosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes AT zmysłowskaagnieszka acrosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes AT borowiecmaciej acrosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes AT młynarskiwojciech acrosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes AT fendlerwojciech acrosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes AT sztromwasserpaweł crosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes AT michalakarkadiusz crosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes AT małachowskabeata crosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes AT młudzikpaulina crosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes AT antosikkarolina crosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes AT hogendorfanna crosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes AT zmysłowskaagnieszka crosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes AT borowiecmaciej crosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes AT młynarskiwojciech crosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes AT fendlerwojciech crosssectionalstudyofpatientsreferredforhnf1bmodygenetictestingduetocystickidneysanddiabetes |